- Home
- / UNITY Biotechnology
UNITY Biotechnology
Stock Price
$1.4
2024-10-29
Market Capitalization
$23.6 M
2024-10-29
Revenue
$236 K
FY, 2022
UNITY Biotechnology Summary
Company Summary
- Overview
- Unity Biotechnology designs therapeutics that prevent various diseases of aging. The company focuses on clearing senescent cells and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.
- Type
- Public
- Status
- Active
- Founded
- 2009
- HQ
- South San Francisco, CA, US | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Nathaniel David, Co-Founder & Director
Lynne Sullivan, Chief Financial Officer and Head of Corporate Development
Sharon Klier, Head of Ophthalmology and Chief Development Officer
LocationsView all
1 location detected
South San Francisco, CA HQ
United States
285 E Grand Ave
UNITY Biotechnology Financials
Summary Financials
- Net income (Q1, 2025)
- ($7.3M)
- Cash (Q1, 2025)
- $8.0M
- EBIT (Q1, 2025)
- ($6.9M)
- Enterprise value
- $38.2M